Loading...
Docoh

Selecta Biosciences (SELB)

Utility
Methods and Compositions for Reducing Immune Responses Against Immunoglobulin Proteases
5 May 22
Disclosed are methods and related compositions for administering an immunoglobulin (Ig) protease in combination with synthetic nanocarriers comprising immunosuppressants.
Takashi Kei Kishimoto
Filed: 4 Nov 21
Utility
Methods of Administering Immunosuppressants Having a Specified Pharmacodynamic Effective Life and Therapeutic Macromolecules for the Induction of Immune Tolerance
10 Mar 22
This invention relates to methods that provide immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules.
Takashi Kei Kishimoto
Filed: 24 Mar 21
Utility
Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses
1 Feb 22
Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods.
David H. Altreuter, Aaron P. Griset, Roberto A. Maldonado
Filed: 6 Aug 18
Utility
Methods and Compositions Related to Synthetic Nanocarriers
7 Oct 21
This invention relates to synthetic nanocarriers, and related compositions and methods, including wherein the synthetic nanocarrier compositions can be lyophilized, are in a lyophilized form, or a reconstituted composition thereof.
Lloyd Johnston
Filed: 11 Mar 21
Utility
Methods and Compositions Using Synthetic Nanocarriers Comprising Immunosuppressant
23 Sep 21
Provided herein are methods and compositions related to synthetic nanocarriers comprising an immunosuppressant that can be used, for example, for inducing autophagy and/or promoting a tolerogenic phenotype.
Petr Ilyinskii, Takashi Kei Kishimoto
Filed: 26 Feb 21
Utility
Formulations and Doses of Pegylated Uricase
24 Jun 21
Provided herein are methods and compositions related to the administration of uricase compositions and compositions comprising synthetic nanocarriers comprising an immunosuppressant for the treatment of subjects, including subjects with hyperuricemia, gout or a condition associated with gout.
Lloyd Johnston, Takashi Kei Kishimoto, Earl Sands, Werner Cautreels
Filed: 6 Nov 20
Utility
Methods and Compositions for Treating Liver Diseases and Disorders
27 May 21
Provided herein are methods and compositions related to compositions comprising synthetic nanocarriers comprising an immunosuppressant.
Petr Ilyinskii, Takashi Kei Kishimoto
Filed: 21 Oct 20
Utility
Methods for administering synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte responses
2 Mar 21
Disclosed are methods for generating humoral and cytotoxic T lymphocyte (CTL) immune responses in a subject and related compositions.
David H. Altreuter, Conlin O'Neil, Petr Ilyinskii
Filed: 27 Jul 12
Utility
Formulations and Doses of Pegylated Uricase
23 Dec 20
Provided herein are methods and compositions and kits related to identification and/or treatment of subjects, including subjects with hyperuricemia, gout or a condition associated with gout, and for preventing gout flare.
Lloyd Johnston, Takashi Kei Kishimoto, Earl Sands, Werner Cautreets
Filed: 3 Jun 20
Utility
Methods and Compositions for Attenuated Anti-viral Transfer Vector Immune Response
16 Dec 20
Provided herein are methods and related compositions or kits for administering viral transfer vectors in combination with synthetic nanocarriers comprising an immunosuppressant and a corticosteroid.
Takashi Kei Kishimoto, Petr Ilyinskii
Filed: 27 May 20
Utility
Nanocarriers Possessing Components with Different Rates of Release
16 Dec 20
This invention relates to compositions, and related methods, of synthetic nanocarriers that comprise immunomodulatory agents and antigens that are differentially released from the synthetic nanocarriers.
Grayson B. Lipford, Charles Zepp, Yun Gao, Mark J. Keegan, Sam Baldwin, Fen-ni Fu, Lloyd Johnston
Filed: 26 Jan 20
Utility
Tolerogenic Synthetic Nanocarriers to Reduce or Prevent Anaphylaxis In Response to a Non-allergenic Antigen
18 Nov 20
This invention relates to methods for reducing or preventing anaphylaxis to non-allergenic antigens with compositions comprising immunosuppressants, and related compositions.
Roberto A. Maldonado
Filed: 23 Apr 20
Utility
Methods for Treatment of Subjects with Preexisting Immunity to Viral Transfer Vectors
18 Nov 20
Provided herein are methods and related compositions for administering viral vectors with synthetic nanocarriers comprising an immunosuppressant to subjects.
Takashi Kei Kishimoto, Petr Ilyinskii
Filed: 27 Apr 20
Utility
Tolerogenic synthetic nanocarriers to reduce or prevent anaphylaxis in response to a non-allergenic antigen
1 Jun 20
This invention relates to methods for reducing or preventing anaphylaxis to non-allergenic antigens with compositions comprising immunosuppressants, and related compositions.
Roberto A. Maldonado
Filed: 1 May 14
Utility
Methods Related to Administering Immunosuppressants and Therapeutic Macromolecules at a Reduced Pharmacodynamically Effective Dose
15 Apr 20
Disclosed are compositions and methods that provide pharmacodynamic effects specific to therapeutic macromolecules.
Roberto A. Maldonado, Takashi Kei Kishimoto
Filed: 25 Aug 19
Utility
Tolerogenic Synthetic Nanocarriers for Antigen-specific Deletion of T Effector Cells
1 Apr 20
Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC Class II-restricted epitopes that can generate tolerogenic immune responses (e.g., antigen-specific T effector cell deletion).
Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
Filed: 7 Aug 19
Utility
Tolerogenic Synthetic Nanocarriers for Generating CD8+ Regulatory T Cells
1 Apr 20
Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells.
Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
Filed: 3 Sep 19
Utility
Methods Providing a Therapeutic Macromolecule and Synthetic Nanocarriers Comprising Immunosuppressant Locally and Concomitantly to Reduce Both Type 1 and Type IV Hypersensitivity
11 Mar 20
Disclosed are methods and related compositions for concomitantly, locally administering immunosuppressants and doses of therapeutic macromolecules for reducing Type I and Type IV hypersensitivity.
Roberto A. Maldonado
Filed: 10 Jun 19
Utility
Methods of Administering Immunosuppressants Having a Specified Pharmacodynamic Effective Life and Therapeutic Macromolecules for the Induction of Immune Tolerance
4 Mar 20
This invention relates to methods that provide immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules.
Takashi Kei Kishimoto
Filed: 12 May 19
Utility
Methods Comprising Dosing Combinations for Reducing Undesired Humoral Immune Responses
4 Mar 20
Disclosed are dosings of therapeutic macromolecules and immunosuppressants, in some embodiments attached to synthetic nanocarriers, in combination with dosings of therapeutic macromolecules without synthetic nanocarriers, and related methods that provide reduced humoral immune responses.
Roberto A. Maldonado, Takashi Kei Kishimoto
Filed: 5 Jun 19
Patents are sorted by USPTO publication date, most recent first